Fludarabine
Peritoneal Cancer
Inge Marie SvaneSmall moleculePhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 81/ 100
Competitive context
37 Active assets in the Peritoneal Cancer cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cyclophosphamide Peking University | Phase 2 | BB |
Docetaxel University of Pittsburgh | Phase 2 | BB |
FLUOROURACILUM City of Hope Medical Center | Phase 3 | BB |
Mirvetuximab Soravtansine AbbVie | Phase 3 | BB |
Carboplatin Qilu Hospital of Shandong University | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →